2022
Use of Whole-Genome Sequencing to Estimate the Contribution of Immune Evasion and Waning Immunity on Decreasing COVID-19 Vaccine Effectiveness
Lind M, Copin R, McCarthy S, Coppi A, Warner F, Ferguson D, Duckwall C, Borg R, Muenker M, Overton J, Hamon S, Zhou A, Cummings D, Ko A, Hamilton J, Schulz W, Hitchings M. Use of Whole-Genome Sequencing to Estimate the Contribution of Immune Evasion and Waning Immunity on Decreasing COVID-19 Vaccine Effectiveness. The Journal Of Infectious Diseases 2022, 227: 663-674. PMID: 36408616, DOI: 10.1093/infdis/jiac453.Peer-Reviewed Original ResearchConceptsVaccine effectivenessImmune evasionDelta infectionVE estimatesSecond doseTest-negative case-control studySevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Whole-genome sequencingCOVID-19 vaccine effectivenessRespiratory syndrome coronavirus 2Syndrome coronavirus 2Case-control studyCoronavirus 2Calendar periodDelta variantInfectionDoseEvasionDaysLow effectivenessImmunityVariantsEffectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
Ranzani OT, Hitchings MDT, de Melo RL, de França GVA, Fernandes CFR, Lind ML, Torres MSS, Tsuha DH, David LCS, Said RFC, Almiron M, de Oliveira RD, Cummings DAT, Dean NE, Andrews JR, Ko AI, Croda J. Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. Nature Communications 2022, 13: 5536. PMID: 36202800, PMCID: PMC9537178, DOI: 10.1038/s41467-022-33169-0.Peer-Reviewed Original Research
1999
Randomized, Double-Blind Study of Stibogluconate Plus Human Granulocyte Macrophage Colony-Stimulating Factor versus Stibogluconate Alone in the Treatment of Cutaneous Leishmaniasis
Almeida R, D'Oliveira A, Machado P, Bacellar O, Ko A, de Jesus A, Mobashery N, Santos J, Carvalho E. Randomized, Double-Blind Study of Stibogluconate Plus Human Granulocyte Macrophage Colony-Stimulating Factor versus Stibogluconate Alone in the Treatment of Cutaneous Leishmaniasis. The Journal Of Infectious Diseases 1999, 180: 1735-1737. PMID: 10515844, DOI: 10.1086/315082.Peer-Reviewed Original ResearchConceptsCutaneous leishmaniasisGM-CSFDouble-blind placebo trialDouble-blind studyRecombinant human granulocyte-macrophage colony-stimulating factorGranulocyte macrophage-colony stimulating factorGM-CSF groupGranulocyte-macrophage colony-stimulating factorMacrophage-colony stimulating factorMacrophage colony-stimulating factorColony-stimulating factorHuman granulocyte macrophage-colony stimulating factorHuman granulocyte-macrophage colony-stimulating factorPlacebo groupPlacebo trialLesion healingSodium stibogluconatePatientsStibogluconateLeishmaniasisLesionsDaysTreatmentPlaceboGroup